Combined PET/CT has been in existence clinically for nearly 7 years since development and initial evaluation from 1998 to 2001. Combined PET/CT offers advantages over PET and CT acquired on separate devices, including consolidation of imaging studies, more accurate data coregistration, improved lesion localization, and benefits related to radiation therapy planning. This article discusses CT and PET protocols pertinent to PET/CT imaging in patients who have head and neck cancer, including a discussion of how the CT portion of a PET/CT scan can be performed and a description of common PET/CT artifacts that may be encountered secondary to CT protocols.
View Article and Find Full Text PDFUnlabelled: PET using 18F-FDG has been shown to effectively detect various types of cancer by their increased glucose metabolism. The aim of this study was to evaluate the use of coregistered PET and CT (PET/CT) in patients with suspected thyroid cancer recurrence.
Methods: After total thyroidectomy followed by radioiodine ablation, 61 consecutive patients with elevated thyroglobulin levels or a clinical suspicion of recurrent disease underwent 18F-FDG PET/CT.
Combined positron emission tomography/computed tomography (PET/CT) became FDA-approved for clinical use in late 2001. There are several design advantages of combined PET/CT over PET and CT acquired on separate devices, including more accurate CT and PET data co-registration, improved lesion localization, consolidation of imaging studies, and reduced scan times compared to dedicated PET. There are several protocols that can used to scan patients on combined PET/CT devices.
View Article and Find Full Text PDFA 43-year-old woman presented with a mass in her left axilla, which was surgically excised. Histologically, the tissue was a reactive lymph node with adjacent thyroid follicular tissue. The differential diagnosis included benign ectopic thyroid versus metastatic well-differentiated follicular-derived thyroid carcinoma.
View Article and Find Full Text PDFPositron emission tomography (PET) with 2-[fluorine-18] fluoro-2-deoxy-D-glucose (FDG) has been effective for the diagnosis, staging, and restaging of malignancies of the head and neck region. However, lack of anatomic landmarks, variable physiologic uptake, and asymmetric FDG distribution in several altered physiologic states can confound image interpretation. In addition, many benign causes and several artifacts can simulate physiologic or pathologic FDG uptake in the head and neck.
View Article and Find Full Text PDFF-18 fluorodeoxyglucose (FDG)-positron emission tomography (PET) is used extensively in oncology to diagnose, stage, and restage patients with various malignancies. Many patients treated for malignancies develop neutropenia secondary to marrow suppressive chemotherapy and are subsequently treated with synthetic hematopoietic growth factors (HGF), both granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte-colony-stimulating factor (G-CSF). Patients taking HGF can present a diagnostic challenge for those interpreting PET because they can demonstrate diffuse marrow uptake on FDG-PET scans, mimicking diffuse bone marrow metastases.
View Article and Find Full Text PDFCancer is one of the leading causes of morbidity and mortality in developed countries such as the United States. Complex clinical decisions about treatment of oncologic patients are largely guided by imaging findings, among other factors. Most radiologic procedures map the anatomy and morphology of tumors with little or no information about their metabolism.
View Article and Find Full Text PDFPurpose: To measure observer performance at various levels of prevalence.
Materials And Methods: A multiobserver multiabnormality receiver operating characteristic (ROC) study to assess the effect of prevalence on observer performance was conducted. Fourteen observers, including eight faculty members, two fellows, and four residents, interpreted 1,632 posteroanterior chest images with five prevalence levels by using a nested study design.
F-18 fluorodeoxyglucose (FDG) positron emission tomography (PET) has been used extensively to stage, restage, and follow neoplastic disease. However, focal accumulation of FDG may cause false-positive results in certain physiologic conditions. In this report, a unique PET and computed tomography (CT) combination scan helped define physiologic accumulation of FDG in the uterus during menstruation in a 40-year-old woman with a history of rectal melanoma and possible recurrent disease.
View Article and Find Full Text PDF